We propose to continue our HIV-1 acute infection and early disease research program (AIEDRP) that uses innovative approaches to recruit 60 or more subjects a year with acute/early HIV infection with high retention rates. Our overall objective is to understand the pathogenic steps in acute HIV infection and find therapeutic approaches to assure a favorable clinical course through enhancement of immune responses. Those subjects enrolled over the past 5 years and newly recruited subjects will constitute a cohort for longitudinal assessment of immunologic, virologic and clinical endpoints of HIV infection. Consenting subjects already on antiviral therapy will be participating in an ongoing STI trial. Other subjects will be randomized to receive combination antiviral treatment with or without IL-2 and with or without immunization with an HIV antigen. We will assess whether immune-based therapies enhance the ability of antiviral drug-treated individuals to maintain immunologic responses to HIV and keep the virus suppressed in blood and genital fluids after interruption of therapy. Subjects who have decided not to receive treatment will be followed and studied as observational controls. The findings should provide valuable information for the long-term control of HIV infection and transmission. Our Specific Objectives are the following: Determine the immunologic features that correlate with low viral load in blood and genital fluids, high CD4+ cell counts, and a healthy clinical state; Determine the optimal treatment approaches that will lead to a desirable immunologic and virologic set point for long-term control of HIV infection; Determine when a selected therapeutic strategy is stopped, which immunologic features prior to treatment interruption correlates with effective control of HIV infection. By investigating acute/early infection with the proposed in-depth virologic and immunologic studies, insights into the basic pathogenesis of HIV infection will be gained. The results should provide useful approaches for both industrialized and developing countries to improve the clinical outcome of infection and block HIV transmission.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M1))
Program Officer
Reese, Karen B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Moore, Camille M; MaWhinney, Samantha; Forster, Jeri E et al. (2017) Accounting for dropout reason in longitudinal studies with nonignorable dropout. Stat Methods Med Res 26:1854-1866
Jain, Vivek; Hartogensis, Wendy; Bacchetti, Peter et al. (2013) Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 208:1202-11
Hecht, Frederick M; Wellman, Robert; Busch, Michael P et al. (2011) Identifying the early post-HIV antibody seroconversion period. J Infect Dis 204:526-33
Meditz, Amie L; MaWhinney, Samantha; Allshouse, Amanda et al. (2011) Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 203:442-51
Willberg, Christian B; Garrison, Keith E; Jones, R Brad et al. (2010) Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One 5:e10249
Hecht, Frederick M; Hartogensis, Wendy; Bragg, Larry et al. (2010) HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24:941-5
Ndhlovu, Lishomwa C; Sinclair, Elizabeth; Epling, Lorrie et al. (2010) IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol 30:681-92
Naeger, David M; Martin, Jeffrey N; Sinclair, Elizabeth et al. (2010) Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 5:e8886
Markowitz, Martin; Vaida, Florin; Hare, C Bradley et al. (2010) The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 201:1298-302
Apuzzo, Linda G; Vaida, Florin; Gallant, Joel E et al. (2009) Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr 50:267-75

Showing the most recent 10 out of 57 publications